Who are Janagliflozin plus metformin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DAPA/MET XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/janagliflozin-plus-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Janagliflozin plus metformin — Competitive Intelligence Brief

Janagliflozin plus metformin (Janagliflozin plus metformin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor + biguanide combination. Area: Diabetes.

phase 3 SGLT2 inhibitor + biguanide combination SGLT2; metformin (mitochondrial complex I) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Janagliflozin plus metformin (Janagliflozin plus metformin) — Sihuan Pharmaceutical Holdings Group Ltd.. Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Janagliflozin plus metformin TARGET	Janagliflozin plus metformin	Sihuan Pharmaceutical Holdings Group Ltd.	phase 3	SGLT2 inhibitor + biguanide combination	SGLT2; metformin (mitochondrial complex I)
DAPA/MET XR	DAPA/MET XR	Woman's	phase 3	SGLT2 inhibitor + biguanide combination	SGLT2; metformin (mitochondrial complex I)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor + biguanide combination class)

Sihuan Pharmaceutical Holdings Group Ltd. · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Janagliflozin plus metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/janagliflozin-plus-metformin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab